BioSpace News Archive

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today presented new data on its masked, anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting taking place in San Diego.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced encouraging first-in-human and first-in-class clinical data demonstrating a promising safety profile and clear evidence of immune system activation via biomarker response.

MiNK Therapeutics, Inc. (NASDAQ: INKT) today presented new agenT-797 data in solid tumor cancers at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”) today presented a poster at the annual meeting of the Society for Immunotherapy of Cancer (SITC), indicating the Company’s ICE® improves cytotoxicity of NK and CAR-NK cells and that NK cells redirected by ICE® exhibit at least the same efficacy against tumor cells as CAR-NK cells alone or redirected by the ICE®.

Medicenna Therapeutics Corp. today announced new preclinical data demonstrating proof of concept for the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) platform technology with the Company’s development candidate, MDNA113, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) held in San Diego, CA, from November 1-5, 2023.